Barclays
CLBTW

Barclays’s Cellebrite DI Ltd. Warrants CLBTW Stock Holding History

Barclays’s Portfolio CLBTW Stock Details CLBTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-192,800
Closed -$149K – 5212
2022
Q2 		$149K Sell
192,800
-11,815
-6% -$10.8K ﹤0.01% 3584
2022
Q1 		$260K Buy
+204,615
New +$258K ﹤0.01% 3269

Other funds holding CLBTW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
CPM
Crescent Park Management East Palo Alto, California $29M AUM 1.79% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
DPCM
Darlington Partners Capital Management Greenbrae, California $2.23B AUM 16.2% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Barclays's CLBTW Position: Q3 2022 in Review

Barclays sold out of Cellebrite DI Ltd. Warrants (CLBTW) in Q3 2022, closing a stake of 192,800 shares — an estimated $149K sold.

Barclays first reported a position in CLBTW in Q1 2022 and held it in 2 quarters. The position peaked at $260K in Q1 2022. 23 funds tracked by Wall St. Rank hold CLBTW as of Q3 2022.

  • Barclays reported no remaining Cellebrite DI Ltd. Warrants position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 192,800 Cellebrite DI Ltd. Warrants shares in Q3 2022, an estimated $149K.
  • Barclays first reported a position in Cellebrite DI Ltd. Warrants in Q1 2022 and held it in 2 quarters.
  • Barclays's Cellebrite DI Ltd. Warrants position peaked at $260K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held Cellebrite DI Ltd. Warrants as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.